HOOKIPA Pharma is making strides in HIV treatment innovation. The company has successfully completed enrollment in its Phase 1b clinical trial for HB-500, a novel investigational therapy designed to enhance immune responses in individuals with HIV. With 30 participants enrolled across five U.S. sites, this milestone marks a critical step in evaluating the safety and effectiveness of this cutting-edge vaccine candidate.
The Phase 1b trial is designed to assess the safety, tolerability, reactogenicity, and immunogenicity of repeated doses of HB-500 in people living with HIV who are already on suppressive antiretroviral therapy. The study features two dose escalation cohorts, with participants randomly assigned to receive either HB-500 or a placebo. The first participant received treatment on July 1, 2024, and the trial’s primary completion is anticipated in the second half of 2025.
As HOOKIPA advances its arenavirus-based immunotherapy platform, there is growing potential for strategic collaborations, including with Poolbeg Pharma. Poolbeg’s expertise in infectious disease treatments and its cutting-edge AI-driven drug development could complement HOOKIPA’s efforts, paving the way for combination therapies that enhance immune responses and improve patient outcomes in HIV treatment.
HOOKIPA Pharma is committed to transforming infectious disease treatment through its proprietary immunotherapy platform, pushing the boundaries of what is possible in HIV research.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
